ES2178650T3 - Uso de terbinafina para el tratamiento terapeutico de neumocitosis. - Google Patents

Uso de terbinafina para el tratamiento terapeutico de neumocitosis.

Info

Publication number
ES2178650T3
ES2178650T3 ES94910517T ES94910517T ES2178650T3 ES 2178650 T3 ES2178650 T3 ES 2178650T3 ES 94910517 T ES94910517 T ES 94910517T ES 94910517 T ES94910517 T ES 94910517T ES 2178650 T3 ES2178650 T3 ES 2178650T3
Authority
ES
Spain
Prior art keywords
terbinafine
pneumocitosis
therapeutic treatment
pneumonia
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94910517T
Other languages
English (en)
Inventor
Simone Claudio De
Carlo Contini
Sonia Tzoutzoglou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VSL Pharma Ltd
Original Assignee
VSL Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VSL Pharma Ltd filed Critical VSL Pharma Ltd
Application granted granted Critical
Publication of ES2178650T3 publication Critical patent/ES2178650T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE PRESENTA EL USO DE LA TERBINAFINA PARA LA PROFILAXIS PRIMARIA Y SECUNDARIA Y EL TRATAMIENTO DE LA NEUMONIA POR LA "PNEUMOCYSTIS CARINII", QUE INCLUYE LA ADMINISTRACION ORAL DE ENTRE 3 Y 20 MM/KG/DIA DE TERBINAFINA A UN SUJETO QUE SUFRA DE ESTE TIPO DE NEUMONIA.
ES94910517T 1993-03-12 1994-03-11 Uso de terbinafina para el tratamiento terapeutico de neumocitosis. Expired - Lifetime ES2178650T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM930154A IT1261776B (it) 1993-03-12 1993-03-12 Uso di terbinafina per il trattamento terapeutico della pneumocistosi.

Publications (1)

Publication Number Publication Date
ES2178650T3 true ES2178650T3 (es) 2003-01-01

Family

ID=11401596

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94910517T Expired - Lifetime ES2178650T3 (es) 1993-03-12 1994-03-11 Uso de terbinafina para el tratamiento terapeutico de neumocitosis.

Country Status (12)

Country Link
US (1) US5719192A (es)
EP (1) EP0692963B1 (es)
JP (1) JPH08508012A (es)
KR (1) KR100343031B1 (es)
AT (1) ATE219667T1 (es)
CA (1) CA2157590C (es)
DE (1) DE69430867T2 (es)
DK (1) DK0692963T3 (es)
ES (1) ES2178650T3 (es)
IT (1) IT1261776B (es)
PT (1) PT692963E (es)
WO (1) WO1994020082A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003360D0 (en) 2000-02-14 2000-04-05 Novartis Ag Monoclonal antibodies
GB0014448D0 (en) * 2000-06-13 2000-08-09 Novartis Ag Organic compounds
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
RU2214237C1 (ru) * 2002-04-24 2003-10-20 Закрытое акционерное общество "Брынцалов-А" Противогрибковое средство "брамизил"
EP1706128B1 (en) 2003-12-08 2010-07-21 CPEX Pharmaceuticals, Inc. Pharmaceutical compositions and methods for insulin treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9111611D0 (en) * 1991-05-30 1991-07-24 Sandoz Ltd Liposomes

Also Published As

Publication number Publication date
ITRM930154A0 (it) 1993-03-12
PT692963E (pt) 2002-10-31
DE69430867T2 (de) 2003-01-02
US5719192A (en) 1998-02-17
KR960700699A (ko) 1996-02-24
IT1261776B (it) 1996-06-03
EP0692963A1 (en) 1996-01-24
KR100343031B1 (ko) 2002-11-07
WO1994020082A1 (en) 1994-09-15
JPH08508012A (ja) 1996-08-27
DK0692963T3 (da) 2002-10-14
ITRM930154A1 (it) 1994-09-12
EP0692963B1 (en) 2002-06-26
CA2157590C (en) 2006-01-10
DE69430867D1 (de) 2002-08-01
ATE219667T1 (de) 2002-07-15
CA2157590A1 (en) 1994-09-15

Similar Documents

Publication Publication Date Title
ES2159184T3 (es) Nueva posologia para la dmni.
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
ES2052717T3 (es) Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.
CO4790174A1 (es) Analogos del peptido lh-rh, sus usos y composiciones farmaceuticas que los contienen
ES2160712T3 (es) Nueva preparacion farmaceutica para tratamiento del dolor.
ID28003A (id) Turunan-turunan adamantana
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
DE69331409D1 (de) Oral 1alpha-hydroxyprevitamin d
BR9407250A (pt) Uso de uma droga tendo atividade vasodilatadora para a fabricação de um medicamento para administração transmucosal transdérmica intranasal e retal
DK0562512T3 (da) Sulfonamidocarbonylpyridin-2-carboxylsyreamider samt deres anvendelse som lægemidler
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
MX9207394A (es) Esteroides de 17-espirofuran-3'-ilideno.
ES2054718T3 (es) El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica.
ES2171459T3 (es) Polvo para administracion nasal de farmaco peptidico o proteinaceo.
ES2178650T3 (es) Uso de terbinafina para el tratamiento terapeutico de neumocitosis.
GR3019274T3 (en) Substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazine-4-ones, their preparation and their therapeutical use
EP0207011A3 (en) Use of some alkanoyl l-carnitines for the therapeutical treatment of idiopathic and induced parkinsonism
BR9713514A (pt) Novo uso de creatina
ES2192608T3 (es) Uso de derivados de alilamina tales como terbinafina, en la fabricacion de un medicamento para el tratamiento de la infeccion por helicobacter pylori de enfermedades asociadas.
ZA866429B (en) P-acylaminobenzamides
ITTO20020684A1 (it) Nuovo uso dell'angelicina e di suoi analoghi strutturali.
HU9602345D0 (en) Diesters of carbonic acid endowed with antiviral and anti-inflammatory activity
MX9203205A (es) Novedosos acidos dimetilamino-hidroxi-alcan-difosfonicos y sales de los mismos, en procedimiento de produccion y composiciones farmaceuticas relacionadas.
BR9812489A (pt) Uso de 6,7-substituìdas-2-aminotetralinas adequadas para a preparação de uma composição farmacêutica para o tratamento terapêutico de patologias inflamatórias e/ou autoimunes
PE20011042A1 (es) Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan